Gold prices hold losses as US-EU trade deal eases safe‑haven demand
Recursion Pharmaceuticals , Inc. (NASDAQ:RXRX), currently trading at $4.32 and showing signs of being undervalued according to InvestingPro Fair Value metrics, has announced the filing of a prospectus supplement and an accompanying base prospectus as part of its automatic shelf Registration Statement on Form S-3ASR, originally filed on February 12, 2025. This filing occurred on May 9, 2025, amid a challenging period that has seen the stock decline 23% in the past week, according to a recent 8-K filing with the Securities and Exchange Commission (SEC).
The prospectus supplement, referred to as the Tempus Prospectus Supplement, was filed to register for resale approximately 4.26 million shares of Recursion’s Class A common stock. These shares were issued to Tempus Labs, Inc. in lieu of annual license fees under a Master Agreement between the two companies, as previously reported in an 8-K filed on November 9, 2023. The distribution of the Tempus Shares is pursuant to an exemption from registration under the Securities Act of 1933, as amended. InvestingPro analysis reveals the company maintains a strong liquidity position with a current ratio of 4.11, indicating robust short-term financial health despite recent market volatility.
The legal opinion regarding the Tempus Shares has been provided by Wilson Sonsini Goodrich & Rosati, P.C., and is included in the filing as Exhibit 5.1. This legal documentation supports the legality of the shares in question.
The 8-K filing provides no further details regarding the financial impact or strategic implications of this registration for Recursion Pharmaceuticals or its shareholders. The information disclosed is based on the 8-K filing with the SEC and is intended to keep investors informed of corporate actions and compliance with securities regulations.
In other recent news, Recursion Pharmaceuticals reported its Q1 2025 financial results, which showed a slight miss on both earnings per share (EPS) and revenue forecasts. The company posted an EPS of -$0.5, missing the forecast of -$0.49, and revenue of $14.75 million, slightly below the expected $14.98 million. BofA Securities responded by revising Recursion’s price target from $10.00 to $8.00 while maintaining a Neutral rating. This adjustment followed the company’s decision to deprioritize four pipeline programs and suspend another clinical program. Despite these challenges, Recursion received a $7 million milestone payment from Sanofi (NASDAQ:SNY), part of a larger deal potentially worth up to $300 million. The merger with Exscientia has prompted a reassessment of Recursion’s platform risks, leading to an updated financial model that reflects a more streamlined pipeline. Recursion’s cash reserves stand at $509 million, which is expected to fund operations into mid-2027.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.